Immune Responses to Haemorrhagic Septicaemia (HS) Vaccination in Trypanosoma Evansi Infected Buffalo-calves
Overview
Veterinary Medicine
Affiliations
To assess the immunosuppressive effect of Trypanosoma evansi infection in buffalo-calves on immune responses to heterologous antigen, the study was planned to examine the responses of haemorrhagic septicaemia vaccination in simultaneously and previously (80 days before vaccination) T. evansi-infected buffalo-calves. Eight buffalo-calves were divided into three groups. Buffalo-calves of group A (n = 3) were previously (80 days before primary vaccination with haemorrhagic septicaemia [HS] vaccine) infected with T. evansi (1 x 10(7) tryps.calf(-1); sc) and that of group B (n = 3) were infected with T. evansi (1 x 10(7) tryps.calf(-1); sc) on the day of primary vaccination with HS vaccine. Two healthy uninfected control calves given only HS vaccine were kept in group C. All the buffalo-calves were given a booster dose of vaccine 21 days post-primary vaccination (PPV). Twenty eight days PPV, animals of group A were given trypanocidal quinapyramine prosalt at 6.66 mg kg(-1). Immunosuppressive effect of T. evansi infection was evident from day 7 PPV with HS vaccine. The effect was more pronounced in previously T. evansi-infected buffalo-calves as compared with simultaneously infected buffalo-calves. Group A buffalo-calves appeared to have recovered from the immunosuppressive effect after 28 days post-trypanocidal treatment as observed by humoral and cell-mediated immune responses. Immunosuppressive effect to HS vaccination was observed in T. evansi-infected buffalo-calves, and trypanocidal therapy enabled the calves to mount the responses similar to uninfected controls.
Comparative Sensitivity and Specificity of the 7SL sRNA Diagnostic Test for Animal Trypanosomiasis.
Contreras Garcia M, Walshe E, Steketee P, Paxton E, Lopez-Vidal J, Pearce M Front Vet Sci. 2022; 9:868912.
PMID: 35450136 PMC: 9017285. DOI: 10.3389/fvets.2022.868912.
Nguyen H, Guevarra R, Magez S, Radwanska M PLoS Pathog. 2021; 17(11):e1010026.
PMID: 34762705 PMC: 8610246. DOI: 10.1371/journal.ppat.1010026.
Radwanska M, Nguyen H, Magez S Vaccines (Basel). 2021; 9(6).
PMID: 34200074 PMC: 8230080. DOI: 10.3390/vaccines9060603.
Magez S, Pinto Torres J, Oh S, Radwanska M Pathogens. 2021; 10(6).
PMID: 34072674 PMC: 8229994. DOI: 10.3390/pathogens10060679.
Magez S, Pinto Torres J, Obishakin E, Radwanska M Front Immunol. 2020; 11:382.
PMID: 32218784 PMC: 7078162. DOI: 10.3389/fimmu.2020.00382.